The global Lysosomal Storage Disorders market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The USA market for Global Lysosomal Storage Disorderseter market is estimated to increase from USD million in 2023 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
The China market for Global Lysosomal Storage Disorders market is estimated to increase from USD million in 2023 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
The Europe market for Global Lysosomal Storage Disorders market is estimated to increase from USD million in 2023 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
The U.S. Market is Estimated at $ Million in 2023, While China is to reach $ Million.
Enzyme Replacement Therapy Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Lysosomal Storage Disorders include Astellas Pharma, Astrazeneca, Actelion, Eli Lilly and Company, Merck & Co, Novo Nordisk, Amicus Therapeutics, Pfizer and Sanofi, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
Lysosomal storage diseases or disorders (LSDs) are?rare genetic conditions that cause a buildup of toxic materials in your body's cells. People with LSDs lack certain enzymes or a substance that helps the enzyme work (enzyme activator or modifier).
This report aims to provide a comprehensive presentation of the global market for Lysosomal Storage Disorders, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Lysosomal Storage Disorders. This report contains market size and forecasts of Lysosomal Storage Disorders in global, including the following market information:
Global Lysosomal Storage Disorders Market Revenue, 2019-2024, 2025-2030, ($ millions)
Global top five companies in 2023 (%)
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Lysosomal Storage Disorders companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Lysosomal Storage Disorders Market, by Type, 2019-2024, 2025-2030 ($ millions)
Global Lysosomal Storage Disorders Market Segment Percentages, by Type, 2023 (%)
- Enzyme Replacement Therapy
- Stem Cell Therapy
- Substrate Reduction Therapy
- Chaperone Therapy
- Others
Global Lysosomal Storage Disorders Market, by Application, 2019-2024, 2025-2030 ($ millions)
Global Lysosomal Storage Disorders Market Segment Percentages, by Application, 2023 (%)
- Hospital
- Clinics
- Stem Cell Transplant Centre
- Research Institutes
- Others
Global Lysosomal Storage Disorders Market, By Region and Country, 2019-2024, 2025-2030 ($ Millions)
Global Lysosomal Storage Disorders Market Segment Percentages, By Region and Country, 2023 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Lysosomal Storage Disorders revenues in global market, 2019-2024 (estimated), ($ millions)
- Key companies Lysosomal Storage Disorders revenues share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Astellas Pharma
- Astrazeneca
- Actelion
- Eli Lilly and Company
- Merck & Co
- Novo Nordisk
- Amicus Therapeutics
- Pfizer
- Sanofi
- BioMarin Pharmaceutical Inc.
- Raptor Pharmaceuticals
- Protalix Biotherapeutics Inc
Outline of Major Chapters:
Chapter 1: Introduces the definition of Lysosomal Storage Disorders, market overview.
Chapter 2: Global Lysosomal Storage Disorders market size in revenue.
Chapter 3: Detailed analysis of Lysosomal Storage Disorders company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Lysosomal Storage Disorders in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
